Causal associations of COVID-19 with health and disease outcomes: a systematic review and meta-analysis

Lidong Gao[a,b1], Junwei Yan[c1], Mengfei Ye [d], Xiaopeng Yang [b], Yiying Yao [b], Jiajia Xia [a], Haonan Jin [a], Shanshan Ru [a], Mengdi Zhang [a], Zheng Liu [b]*, Yingzhe Zhang[a]*

[a] Department of Pharmacy, Shaoxing Central Hospital (Affiliated Central Hospital of Shaoxing University), Shaoxing, Zhejiang, China

[b] Department of Behavioral Neurosciences, Science Research Center of Medical School, Shaoxing University, Shaoxing, Zhejiang, China

[c] Department of Blood Transfusion, Affiliated Hospital of Shaoxing University, Shaoxing, Zhejiang, China

[d] Department of Psychiatry, Shaoxing Seventh People's Hospital (Affiliated Mental Health Center, Medical College of Shaoxing University), Shaoxing, Zhejiang, China

* Correspondence:

Zheng Liu, E-mail: liuzheng1707@163.com; No.900 Chengnan Avenue, Yuecheng District, Shaoxing 312000, Zhejiang, China

Yingzhe Zhang, E-mail: zyzlcl@126.com; No.1 Huayu Road, Keqiao District, Shaoxing 312000, Zhejiang, China

1 These authors contributed equally to this work.

Causal associations of COVID-19 with health and disease outcomes: a systematic review and meta-analysis

Abstract

Objectives The COVID-19 pandemic has posed a substantial threat to global health. Despite numerous clinical observations and causality investigations, understanding of the disease's progression and recovery process following infection remains limited. This systematic review and meta-analysis evaluates the causal connections between COVID-19 and various diseases using Mendelian randomization studies to provide robust theoretical underpinnings for the development of effective rehabilitation and intervention strategies.

Methods We systematically searched PubMed, Embase, Web of Science, and Scopus for studies on Mendelian randomization related to COVID-19 published up to October 21, 2024. We used an extensive search strategy with the keywords "Mendelian randomization" and "COVID-19". Two pairs of coauthors independently extracted data on study characteristics, exposure, and outcomes, resolving discrepancies through discussion. We included studies that considered susceptibility to COVID-19, hospitalization, or severe infection as the exposure and disease-related effects or impacts on human health as outcomes. We assessed the quality of the included studies using the MR-STROBE criteria and extracted the relative risk (odds ratio [OR]) using a random-effects model for meta-analysis. This study is registered with PROSPERO, CRD42025615426.

Results Of the 1654 studies identified, 87 met the inclusion criteria for our meta-analysis. The primary outcome suggests that COVID-19 is associated with an increased risk of cardio-cerebral vascular diseases. Subgroup analyses identified an increased risk of neuropsychiatric disorders, including optic nerve disorders, epilepsy, schizophrenia,

generalized anxiety disorder, stroke, myocardial infarction with COVID-19. There is also a notable association between COVID-19 and the immune system, particularly neuromyelitis optica spectrum disorders and myasthenia gravis.

Conclusions This study demonstrates that COVID-19 infection has direct causal effects on human health or certain diseases at the genetic level, which may manifest as increased or decreased susceptibility to disease and changes in disease severity.

Keywords: COVID-19, Mendelian randomization, health and diseases, meta-analysis, causal relationship

Introduction

COVID-19 is a life-threatening infectious disease caused by SARS-CoV-2, first identified in Wuhan, China, in November 2019. Since then, it has spread rapidly around the world, leading the World Health Organization to classify it as a pandemic in March 2020.[1] The clinical manifestations of COVID-19 range from asymptomatic infection to severe illness requiring intensive care, and occasionally resulting in death.[2] Emerging evidence suggests that the clinical burden of COVID-19 extends beyond the acute phase, affecting patients' quality of life and posing a significant challenge to global health.[3]

Our understanding of the COVID-19 pandemic has evolved with studies describing its epidemiology, clinical characteristics, pathophysiology, and complications. However, the long-term consequences of the disease remain largely unclear, despite many clinicians having observed a variety of extrapulmonary manifestations associated with COVID-19.[4] A systematic review identified 84 clinical signs or persistent symptoms as most common among 45 studies of post-COVID-19 individuals, with newly emerged diseases such as cardiovascular dysfunction, urinary system symptoms, and neurological disorders occurring more frequently.[5] Therefore, exploring the impact of COVID-19 on human physiology or disease progression has significant implications for patient prognosis and subsequent infections.

Numerous researchers have investigated the associations between COVID-19 and various systemic diseases or health outcomes, but a comprehensive synthesis of these studies is lacking. Conflicting findings emerge from studies examining the same outcomes. For instance, a bidirectional study suggests that the causal link between genetic predisposition to SARS-CoV-2 infection and cognitive decline might be mediated by systemic inflammation.[6] Conversely, another study,

employing a reverse Mendelian Randomization (MR) analysis of COVID-19, revealed a non-significant association between exposure and cognitive performance, suggesting a unidirectional relationship.[7] These reports are inconclusive regarding both clinical observations and causal inference. However, We searched PubMed, Embase, Web of Science, and Scopus for studies relate to “COVID-19”, “meta-analysis” and “Mendelian randomization” up to October 21, 2024, no systematic review has evaluated the quality of this causal evidence, and previous meta-analyses have not included MR studies. To comprehensively assess and summarize the evidence for the causal role of COVID-19 in multiple diseases, we conducted a systematic review and meta-analysis of published MR studies.

Methods

Literature Search and Inclusion Criteria

We conducted a systematic search of PubMed, Scopus, Embase, and Web of science databases for studies related to COVID-19 and MR up to October 21, 2024. The search strategy incorporated the terms “Mendelian randomization” and “COVID-19”. We included original full-text articles that reported associations between COVID-19 and risks to various health outcomes, including the central nervous system disease, cardio-cerebrovascular system disease, digestive system disease, immune system disease, endocrine system disease, genitourinary system disease, tumors and infectious diseases. When multiple publications reported outcomes based on the same Genome-Wide Association Studies (GWAS), we selected the publication with the largest sample size for COVID-19. Studies that did not fall within the above systems were excluded due to the limited number of studies, which precluded meta-analysis their estimates with other eligible studies. The studies were performed in accordance with the PRIMA and STROBE-MR guidelines.

Data Extraction and Quality Assessment

Data extraction was conducted for each study, capturing details such as the first author's family name, publication year, the consortium or study providing genetic variants related to COVID-19 exposure, the consortium or study supplying genetic association estimates for the disease, sample size indicated by the number of cases and non-cases, and the relative risk estimate expressed as the the odds ratio (OR) with the corresponding 95% confidence interval (CI) for the association with COVID-19. These estimates were derived from the main analysis using the inverse-variance weighted method, sensitivity analyses using the weighted median and MR-Egger methods, and a multivariable MR analysis adjusted for genetically predicted COVID-19. Data extraction was performed by one investigator and verified by another.

To ensure the transparency and quality of the research, we referred to the STROBE-MR guidelines for assessing the quality of included MR studies.

Data Analysis

For outcomes with multiple MR estimates from non-overlapping samples, we derived a pooled estimate through meta-analysis using the metan command in Stata (version 12). We employed a random-effects model to estimate the impact of COVID-19 on human health or the disease progression. Most reported estimates were expressed in terms of the per standard deviation increase in the risk of COVID-19 susceptibility, hospitalization, or severe infection. Heterogeneity across studies was assessed using the I^2 statistic. We interpreted I^2 values of 25-50% as indicating mild heterogeneity, 50-75% as moderate heterogeneity, and >75% as severe heterogeneity. Publication bias was evaluated through visual inspection of the forest plots, and statistical significance was set at a two-tailed P-value of less than 0.05 for all analyses. For

outcomes with considerable heterogeneity (I^2 between 50% and 75%), subgroup analysis was conducted to explore tween-study heterogeneity. Sensitivity analysis included outlier detection and influence diagnostics, such as leave-one-out cross-validation.

Results

Literature search, study selection

Our database search yielded 1654 records, which were reduced to 516 after removing duplicates. After excluding studies with overlapping or identical outcome data, 87 articles based on non-overlapping populations were eligible for inclusion in the meta-analyses (Figure 1). The distribution of included studies across outcome categories was as follows: 23 for central nervous system disease,[7-30] 16 for cardio-cerebrovascular system,[31-46] 5 for digestive system disease,[47-52] 15 for autoimmune disease,[53-67] 2 for endocrine system disease,[68 69] 8 for genitourinary system disease,[70-77] 12 for tumors,[78-89] 3 for infectious diseases,[90-92] 3 for multisystem disease.[93-95] The quality assessment and results from the studies included in this review are shown in eTable 2. The methodological quality of the studies included was assessed as moderate.

Study Description

The characteristics of the MR studies indicating causal relationships are presented in eTable 1. Out of 87 studies, 18 employed a bidirectional MR study design, allowing for the examination of causality in both directions. In most studies, the genetic variations of exposure originated from the COVID-19 Host Genetics Initiative. Although the version of the data and, consequently, the sample size varied across studies, this variation did not impact the overall findings.

Meta-Analysis Results

Mendelian randomized studies[31-46 95] evaluating the effects of COVID-19

on the cardio-cerebrovascular system showed a positive correlation between genetic predisposition and the risk of COVID-19 (OR 1.013, 95% CI 1.006-1.019). Furthermore, the risk of COVID-19 was positively correlated with pre-existing cardiovascular and cerebrovascular disease (OR 1.019, 95% CI 1.011-1.027). (Figure 2)

Subgroup analysis

We identified significant heterogeneity in some of the meta-analysis results. To determine the source of this variability, we performed subgroup analyses to further explore the causal relationship between COVID-19 and the disorders (eTable 3).

In the subgroup analyses (Figure 3), a positive correlation was observed between COVID-19 and epilepsy, with an OR of 1.087 and a 95% CI ranging from 1.053 to 1.122.[16 20 22 23 28] We also analyzed the three severity levels of COVID-19 with epilepsy (Table 1), finding that susceptibility to COVID-19, hospitalization status, and severe infection had a positive impact on epilepsy, with ORs of 1.081 (95% CI 1.021-1.167), 1.092 (95% CI 1.033-1.151) and 1.066 (95% CI 1.015-1.116), respectively.

Interestingly, hospitalization and severe COVID-19 infection were positively associated with both focal and generalized epilepsy, with ORs of 1.655 (95% CI 1.101-2.209), 1.667 (95% CI 1.288- 2.046), 1.203 (95% CI 1.074-1.332) and 1.077 (95% CI 0.975-1.179), respectively. Additionally, hospitalization due to COVID-19 showed a positive effect on eclampsia and pre-eclampsia, with ORs of 1.075 (95% CI 1.866-1.284) and 1.159 (95% CI 1.057-1.262), respectively.

Conversely, COVID-19 demonstrated a negative correlation with cognitive dysfunction[96] with ORs of 0.86 (95% CI 0.774-0.945). Furthermore, COVID-19 was found to be positively correlated with optic nerve disorders, schizophrenia and generalized anxiety disorder, with

ORs of 1.444 (95% CI 1.080-1.807),[25 30] 1.048 (95% CI 1.014-1.081)[8 9 21] and 1.01 (95% CI 1.006-1.015)[9 21], respectively (Figure 3).

In the context of the cardiovascular and cerebrovascular systems, COVID-19 has been found to have a positive association with stroke. The OR for stroke was 1.031 with a 95% CI of 1.018 to 1.043.[23 32 37 40] In contrast, COVID-19 exhibited a negative correlation with myocardial infarction and pericarditis, both with ORs of 0.978 and a 95% CI of 0.962 to 0.993 and 0.900 and a 95% CI of 0.825 to 0.975 (Figure 3).

In the digestive system, the meta-analysis outcomes indicated a positive correlation between COVID-19 and irritable bowel syndrome, with an OR of 1.039 and a 95% CI of 1.014-1.063.[50] Additionally, COVID-19 was found to have a positive correlation with type 2 diabetes mellitus, with an OR of 1.076 and a 95% CI of 1.022-1.129.[69 95] (Figure 3)

While COVID-19 has no overall effect on the immune system, our meta-analysis results indicated that COVID-19 was positively correlated with neuromyelitis optica spectrum disorders (OR 1.292, 95% CI 1.043-1.543).[58 60] Additionally, COVID-19 had a positive effect on myasthenia gravis and celiac disease, with ORs of 1.096 and a 95% CI of 1.029-1.162[59] and 1.111 and a 95% CI of 1.011-1.211[65] (Figure 3). Conversely, COVID-19 had a negative effect with rheumatoid arthritis, with an OR of 0.976 and a 95% CI of 0.954-0.999.

In the context of the urogenital system, our meta-analysis indicated a positive association between COVID-19 and lower urinary tract symptoms, with an OR of 1.293 and a 95% CI of 1.043-1.543 (Figure 3).[71]

Furthermore, our study revealed a positive correlation between COVID-19 and various reproductive disorders.[71] Specifically, there was a positive association between COVID-19 and sexual dysfunction, with an OR of 1.093 and a 95% CI of 1.026-1.16. This correlation suggests a heightened

risk of sexual dysfunction in individuals with COVID-19 infection. COVID-19 was also positively linked to testicular dysfunction, with an OR of 1.326 and a 95% CI of 1.095-1.557. This finding implies a significantly increased risk of testicular dysfunction in the presence of COVID-19. In contrast, COVID-19 showed a negative correlation with torsion of the testis, with an OR of 0.772 and a 95% CI of 0.554-0.99 (Figure 3). This inverse relationship suggests that the risk of testicular torsion might be reduced in individuals with COVID-19.

Discussion

This meta-analysis reveals a strong link between COVID-19 and heightened risks for multiple systemic diseases, including neuropsychiatric disorders (epilepsy, anxiety, schizophrenia), cerebrovascular diseases (stroke, thromboembolism), gastrointestinal issues (irritable bowel syndrome), endocrine diseases (type 2 diabetes), and autoimmune conditions (myasthenia gravis, neuromyelitis optica). The virus also impacts urinary and reproductive health, raising risks for lower urinary tract symptoms, erectile dysfunction, and testicular issues. Interestingly, COVID-19 infection seems to correlate with a lower likelihood of cognitive dysfunction, certain cardiac conditions (myocardial infarction, pericarditis), and testicular torsion.

It is well-established that angiotensin-converting enzyme 2 (ACE2) plays a pivotal role in both cardiovascular and immune system functions. Clinical studies have shown that SARS-CoV-2, the virus causing COVID-19, targets the ACE2 receptor to enter host cells, leading to acute myocardial injury and chronic cardiovascular complications.[97] This can influence the progression or worsening of conditions such as stroke, diabetes, and myocardial infarction. [98] [99] Additionally, a spectrum of neurological symptoms, including headaches, dizziness, altered consciousness, acute cerebrovascular events, ataxia, and epileptic seizures,

have been documented post-COVID-19 infection. [100] Our research underscores that the consequences of COVID-19 extend beyond the acute phase, encompassing a wide array of long-term health impacts.

Our study has identified COVID-19 infection as a contributing factor in the onset or progression of epilepsy and stroke, aligning with previous clinical research that has observed alterations in mental state and cerebrovascular incidents among COVID-19 patients with neurological or psychiatric conditions.[101] Despite some reports indicating that COVID-19 symptoms are predominantly respiratory or gastrointestinal and not typically associated with epileptic seizures,[102] our research employs a Mendelian approach to infer causality using genetic variants as instrumental variables, thereby mitigating the impact of confounding factors. Our meta-research, in line with previous MR studies, consistently concludes that COVID-19 infection elevates the risk of epilepsy. Moreover, our findings reveal a statistically significant association between COVID-19 infection and cognitive disorders, optic nerve disorders, anxiety, and schizophrenia. However, given the limited number of studies included, further MR research is warranted to substantiate these findings. Regarding stroke, a meta-analysis has shown that patients with severe COVID-19 infection are at a higher risk of stroke.[103] While this study discusses potential mechanisms for stroke and myocardial infarction in COVID-19 patients, the exact pathways remain to be elucidated.

Strengths and Limitations

Our research boasts a number of significant strengths. It offers a comprehensive assessment of the causal links between COVID-19 and a spectrum of health outcomes, a contribution that is pioneering within the academic landscape. Adhering to the rigorous PRIMA and STROBE-MR guidelines, we've ensured a high standard of methodological integrity.

The inclusion of a diverse array of studies from various databases and sources enhances both the robustness and the broad applicability of our findings. Most notably, our study delves into the genetic level impacts of COVID-19 on health, shedding light on its influence on disease susceptibility and severity, and offering fresh perspectives on the pandemic's long-term health implications.

Our study, while insightful, has limitations. Aggregated data limits detailed patient insights, and a focus on European descendants may restrict the universality of our findings. Unmeasured confounders could affect associations, and we've assumed a linear relationship between COVID-19 and health outcomes, which may not capture all complexities. Future research should aim for large-scale, multicenter trials to solidify causal evidence between COVID-19 and health outcomes, providing a stronger basis for interventions and understanding long-term effects.

Conclusion

In conclusion, our study systematically explored the causal relationships between COVID-19 and health outcomes across multiple human systems through meta-analysis of MR studies. We demonstrate that that COVID-19 increases the risk of diseases associated with the central nervous system and cardiovascular and cerebrovascular systems. Our study offers fresh insights, highlighting the need to delve into the long-term effects of COVID-19 and possible interventions. This research is crucial for a global evaluation of the pandemic's impact and will lay the groundwork for strategies to alleviate the enduring health burden caused by COVID-19.

Contributors

LD, ZL, and YZ conceived and designed the study. LD, JW, MF, YY, XP, JJ, and HN acquired data. LD, JW, JJ, MD, and ZL analysed data. LD, JW, MF, YY, and XP interpreted the data. LD and YZ drafted the Article. ZL

and MF critically revised the Article. All authors reviewed the submitted version of the manuscript and approved the final version of the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Declaration of interests

We declare no competing interests.

Clinical trial number: not applicable.

Data sharing

All data included were derived from publicly available documents cited in the references. Extracted data are available upon request to the corresponding author.

Acknowledgments

This work was funded by the Zhejiang Medical and Health Science and Technology Project (No.2024KY484), the Shaoxing Health Science and Technology Project (No.2023SKY073), the Science and Technology Planning Project of Shaoxing City (No. 2023A14030), and Shaoxing University Enterprise Important Horizontal Topic (No. 2024USXH287).

Figures and Table Legends

Fig.1 Flowchart of literature search, MR and meta-analysis.

This flowchart provides a detailed overview of the research process. It includes the processes of literature search, screening, eligibility assessment, and the number of data points included in the meta-analysis.

Fig.2 Forest plot of meta-analysis on the impact of COVID-19 on major human systems. AD, Autoimmunity diseases; CI, Confidence intervals; CNS, Central nervous system; CSFCs, Cardiac structural functional changes; CVD, Cardiovascular diseases; CVS, Cardiovascular and cerebrovascular diseases; DS, Digestive system; ES, Endocrinium

diseases; GU, Genitourinary diseases; IDs, Infectious diseases; MS, Mental system diseases; NS, Nervous system diseases; OR, Odds ratio; Rs, Reproductive system; Tu, Tumour; US, Urinary system.

Fig.3 Subgroup analysis results.

This figure, which includes a heatmap and a forest plot, reflects the subgroup results of a MR meta-analysis on the effects of three B vitamins on fifteen neuropsychiatric disorders. AD, Autoimmunity dieases; CI, Confidence intervals; CNS, Central nervous system; CVS, Cardiovascular and cerebrovascular diseases; DS, Digestive system; EC, Endometrial cancer; ES, Endocrinium dieases; GAD, Generalized anxiety disorder; GBM, Glioblastoma multiforme; GU, Genitourinary dieases; IBS, Irritable bowel syndrome; MG, Myasthenia gravis; MI, Myocardial infarction; NMOSD, Neuromyelitis optica spectrum disorder; OR, Odds ratio; RA, Rheumatoid Arthritis; SCZ, Schizophrenia; Tu, Tumor; T2DM, Type 2 Diabetes mellitus.

Table 1 Positive causal relationship between COVID-19 and epilepsy through subgroup meta-analysis.

Study	Odds ratio **(LCI, UCI) - random effects model**		
	COVID-19 Susceptibility	COVID-19 Hospitalized	COVID-19 Severity
Epilepsy			
Dai et al [2024]	0.990(0.950, 1.030)	1.000(0.970, 1.040)	0.990(0.950, 1.030)
He et al [2023]	0.990(0.860, 1.140)	1.000(0.960, 1.040)	0.990(0.960, 1.010)
You et al [2023]	**1.344(1.024, 1.765)**	**1.093(1.010, 1.184)**	**1.245(1.085, 1.430)**
You et al [2023]	**1.531(1.168, 2.006)**	**1.738(1.047, 2.886)**	**1.272(1.035, 1.565)**
Subtotal	1.093(0.935, 1.251) **(I^2=68.8%, P=0.022)**	1.019(0.973, 1.064) **(I^2=52.8%, P=0.095)**	1.037(0.969, 1.105) **(I^2=76.9%, P=0.005)**
Focal epilepsy			
You et al [2023]	1.016(0.627, 1.498)	**1.585(1.010, 2.486)**	**1.660(1.257, 2.191)**
You et al [2023]	1.087(0.972, 1.216)	**1.755(1.106, 2.784)**	**1.682(1.148, 2.464)**
Subtotal	1.085(0.965, 1.205) **(I^2=0.00%, P=0.762)**	**1.655(1.101, 2.209)** **(I^2=0.00%, P=0.765)**	**1.667(1.288, 2.046)** **(I^2=0.00%, P=0.961)**
Generalized epilepsy			
You et al [2023]	**1.125(1.044, 1.211)**	**1.183(1.022, 1.369)**	**1.044(1.016, 1.073)**
You et al [2023]	**2.116(1.173, 3.814)**	**1.228(1.051, 1.435)**	**1.149(1.027, 1.284)**
Subtotal	1.394(0.520, 2.268) **(I^2=54.5%, P=0.138)**	**1.203(1.074, 1.332)** **(I^2=0.00%, P=0.704)**	**1.077(0.975, 1.179)** **(I^2=65.0%, P=0.091)**
Eclampsia			
Wu et al [2024]	0.440(0.180, 1.110)	0.900(0.610, 1.310)	0.930(0.690, 1.250)
Xing et al [2023]	1.220(0.990, 1.510)	**1.140(1.010, 1.300)**	
Subtotal	1.855(0.092, 1.618) **(I^2=87.9%, P=0.004)**	**1.075(1.866, 1.284)** **(I^2=35.1%, P=0.214)**	
Pre-eclampsia			
Wu et al [2024]	1.150(0.880, 1.520)	**1.170(1.030, 1.330)**	**1.100(1.010, 1.190)**
Xing et al [2023]	**1.230(1.010, 1.510)**	**1.150(1.020, 1.300)**	
Subtotal	1.200(1.003, 1.397) **(I^2=0.00%, P=0.699)**	**1.159(1.057, 1.262)** **(I^2=0.00%, P=0.848)**	
Overall	**1.081 (1.021, 1.167)** **(I^2=64.9%, P=0.001)**	**1.092 (1.033.1.151)** **(I^2=63.4%, P=0.002)**	**1.066 (1.015, 1.116)** **(I^2= 77.1%, P=0.000)**

REFERENCES

1 Cucinotta D, Vanelli M. Who declares covid-19 a pandemic. *Acta Biomed* 2020;91:157-60.

2 Wu Z, Mcgoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in china: summary of a report of 72□314 cases from the chinese center for disease control and prevention. *JAMA.* 2020;323:1239-42.

3 Cevik M, Kuppalli K, Kindrachuk J, *et al*. Virology, transmission, and pathogenesis of SARS-cov-2. 2020.

4 Gupta A, Madhavan MV, Sehgal K, *et al*. Extrapulmonary manifestations of covid-19. *Nat. Med*. 2020;26:1017-32.

5 Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with covid-19: a systematic review. *JAMA Netw. Open* 2021;4:e2111417.

6 Tang CM, Li GH, Cheung CL. Covid-19 and cognitive performance: a mendelian randomization study. *Front. Public Health* 2023;11:1185957.

7 Ran S, Yao J, Liu B. The association between covid-19 and cognitive performance: a mendelian randomization analysis. *Alzheimer's & Dementia* 2023;19:2742-4.

8 Baranova A, Cao H, Zhang F. Severe covid-19 increases the risk of schizophrenia. *Psychiatry Res.* 2022;317:114809.

9 Tirozzi A, Santonastaso F, de Gaetano G, *et al*. Does covid-19 increase the risk of neuropsychiatric sequelae? Evidence from a mendelian randomization approach. *World J. Psychiatry* 2022;12:536-40.

10 Zhang H, Zhou Z. Covid -19 and the risk of alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis. *Ann. Clin. Transl. Neurol.* 2022;9:1953-61.

11 Zhu G, Zhou S, Xu Y, *et al*. Mendelian randomization study on the causal effects of covid-19 on childhood intelligence. *J. Med. Virol.* 2022;94:3233-9.

12 Baranova A, Zhao Y, Cao H, *et al*. Causal associations between major depressive disorder and covid-19. *Gen. Psychiat.* 2023;36:e101006.

13 Cao H, Baranova A, Song Y, *et al*. Causal associations and genetic overlap between covid-19 and intelligence. *QJM: An International Journal of Medicine* 2023;116:766-73.

14 Chen F, Cao H, Baranova A, *et al*. Causal associations between covid-19 and childhood mental disorders. *BMC Psychiatry* 2023;23:922.

15 Ding P, Gurney M, Perry G, *et al*. Association of covid-19 with risk and progression of alzheimer's disease: non-overlapping two-sample mendelian randomization analysis of 2.6 million subjects. *Journal of Alzheimer's Disease* 2023;96:1711-20.

16 He Z, Li Y, Liu S, *et al*. Mendelian randomization reveals no causal relationship between covid-19 susceptibility, hospitalization, or severity and epilepsy. *Epilepsia Open* 2023;8:1452-

9.
17 Li Z, Dang W, Hao T, *et al*. Shared genetics and causal relationships between major depressive disorder and covid-19 related traits: a large-scale genome-wide cross-trait meta-analysis. *Front. Psychiatry* 2023;14:1144697.
18 Ran S, Wu Y, Liu B. Association between insomnia and covid-19: a bi-directional mendelian randomization analysis. *Sleep Med.* 2023;105:43-4.
19 Sun D, Wang R, Shi Z, *et al*. Causal relationship of covid-19 on alzheimer's disease: an updated mendelian randomization study. *Neurol. Sci*. 2023;44:2643-4.
20 Xing Y, Wang Z, Qi X, *et al*. Genetic liability between covid-19 and pre-eclampsia/eclampsia: a mendelian randomization study. *Hypertens. Pregnancy* 2023;42:2285757.
21 Xue H, Zeng L, Liu S. Susceptibility and severity of covid-19 and risk of psychiatric disorders in european populations: a mendelian randomization study. *Front. Psychiatry* 2023;14:1253051.
22 You M, Yuan P, Li L, *et al*. The association between epilepsy and covid-19: analysis based on mendelian randomization and fuma. *Front. Neurosci*. 2023;17:1235822.
23 Dai L, Lyu L, Zhou P, *et al*. Causal associations of covid-19 on neurosurgical diseases risk: a mendelian randomization study. *Hum. Genomics* 2024;18:13.
24 Huang L, Wang Y, He Y, *et al*. Association between covid-19 and neurological diseases: evidence from large-scale mendelian randomization analysis and single-cell rna sequencing analysis. *Mol. Neurobiol.* 2024.
25 Pan Y, Zhang J, He T. SARS-cov-2 neurovascular invasion supported by mendelian randomization. *J. Transl. Med.* 2024;22:101.
26 Jiang H, Zhang C, Meng X, *et al*. Covid-19, vaccination and migraine: causal association or epiphenomenon? *PLoS One* 2024;19:e308151.
27 Baranova A, Fu L, Song Y, *et al*. Causal associations between posttraumatic stress disorder and covid-19. *J. Integr. Neurosci.* 2024;23:68.
28 Wu W, Zhang J, Qiao Y, *et al*. Mendelian randomization supports genetic liability to hospitalization for covid-19 as a risk factor of pre-eclampsia. *Front. Cardiovasc. Med.* 2024;11.
29 Monistrol-Mula A, Diaz-Torres S, Felez-Nobrega M, *et al*. Genetic analyses point to alterations in immune-related pathways underpinning the association between psychiatric disorders and covid-19. *Mol. Psychiatry* 2024.
30 Cao C, Li Q, Cai D, *et al*. Causal effect of covid-19 on optic nerve and visual pathway disorders: genetic evidence of lung-brain axis. *Front. Immunol.* 2024;15.
31 Tan J, Liu N, Guo T, *et al*. Genetic predisposition to covid-19 may increase the risk of hypertension disorders in pregnancy: a two-sample mendelian randomization study. *Pregnancy Hypertension* 2021;26:17-23.
32 Zuber V, Cameron A, Myserlis EP, *et al*. Leveraging genetic data to elucidate the relationship between covid-19 and ischemic stroke. *J. Am. Heart Assoc.* 2021;10.
33 Jia M, Chen H, Jia L, *et al*. Genetic predisposition to coronavirus disease 2019 in relation to

ten cardiovascular conditions: a two-sample mendelian randomization study. *Front. Med.* 2022;9:796165.

34 Tan J, Liu N, Guo T, *et al*. Genetic predispositions between covid-19 and three cardio-cerebrovascular diseases. *Front. Genet.* 2022;13:743905.

35 Wang H, Guo Z, Zheng Y, *et al*. Genetic liability between covid-19 and heart failure: evidence from a bidirectional mendelian randomization study. *BMC Cardiovasc. Disord.* 2022;22:262.

36 Zhang X, Wang B, Geng T, *et al*. Causal associations between covid-19 and atrial fibrillation: a bidirectional mendelian randomization study. *Nutrition, Metabolism and Cardiovascular Diseases* 2022;32:1001-9.

37 Zhang J, Wu F, Chen S, *et al*. Genetic predisposition to severe covid-19 might increase the risk of stroke: a two-sample mendelian randomization study. *Front. Genet.* 2022;13:895211.

38 Huang X, Yao M, Tian P, *et al*. Genome-wide cross-trait analysis and mendelian randomization reveal a shared genetic etiology and causality between covid-19 and venous thromboembolism. *Commun. Biol.* 2023;6:441.

39 Liu G, Chen T, Zhang X, *et al*. Causal relationship between covid-19 and myocarditis or pericarditis risk: a bidirectional mendelian randomization study. *Front. Cardiovasc. Med.* 2023;10:1271959.

40 Ma J, Qiu S. Infection with critically ill covid-19 increases the risk of cardioembolic stroke. *J. Med. Virol.* 2023;95.

41 Wang S, Peng H, Chen F, *et al*. Identification of genetic loci jointly influencing covid-19 and coronary heart diseases. *Hum. Genomics* 2023;17:101.

42 Zheng Z, Zhou Y, Song Y, *et al*. Genetic and immunological insights into covid-19 with acute myocardial infarction: integrated analysis of mendelian randomization, transcriptomics, and clinical samples. *Front. Immunol.* 2023;14:1286087.

43 Li M, Xiao L, Cai J, *et al*. Absence of a causal link between covid-19 and deep vein thrombosis: insights from a bi-directional mendelian randomisation study. *J. Glob. Health* 2024;14:5001.

44 Li Y, Yang D, Kang J, *et al*. Covid-19 and the risk of acute cardiovascular diseases: a two-sample mendelian randomization study. *BMC Cardiovasc. Disord.* 2024;24.

45 Tang X, Zhuang H, Yu H. A bidirectional mendelian randomization analysis between covid-19 and cardiac arrest. *Int. J. Environ. Health Res.* 2024:1-12.

46 Wang H, Wu S, Pan D, *et al*. Causal relationships between covid-19 and venous thromboembolism: a mendelian randomization analysis. *Phlebology: The Journal of Venous Disease* 2024.

47 Liu D, Zhang Q, Bai P, *et al*. Assessing causal relationships between covid-19 and non-alcoholic fatty liver disease. *J. Hepatol.* 2022;76:740-2.

48 Ge P, Luo Y, Liu J, *et al*. Eliminating covid-19 as the immediate culprit for igniting pancreatitis. *J. Med. Virol.* 2023;95.

49 Li Z, Zhu G, Lei X, *et al*. Genetic support of the causal association between gut microbiome and covid-19: a bidirectional mendelian randomization study. *Front. Immunol.* 2023;14:1217615.

50 Wang Z, Zhou H, Zhang S, *et al*. The causal relationship between covid-19 and seventeen common digestive diseases: a two-sample, multivariable mendelian randomization study. *Hum. Genomics* 2023;17:87.
51 Chen H, Ye B, Su W, *et al*. The causal role of gut microbiota in susceptibility and severity of covid-19: a bidirectional mendelian randomization study. *J. Med. Virol.* 2023;95.
52 He X, Li Y, Liu J, *et al*. The causal relationship between covid-19 and ten esophageal diseases: a study utilizing mendelian randomization. *Front. Med.* 2024;11.
53 Peng H, Wu X, Xiong S, *et al*. Gout and susceptibility and severity of covid-19: a bidirectional mendelian randomization analysis. *J. Infect.* 2022;85:e59-61.
54 Ran S, Pan L, Liu B. Are patients with systemic lupus erythematosus at increased risk for covid-19? A bi-directional mendelian randomisation study. *Lupus Sci. Med.* 2022;9:e786.
55 Chalitsios CV, Tsilidis KK, Tzoulaki I. Psoriasis and covid-19: a bidirectional mendelian randomization study. *J. Am. Acad. Dermatol.* 2023;88:893-5.
56 Luo M, Zhu C, Lin J, *et al*. Bidirectional mendelian randomization analysis did not indicate a causal relationship between atopic dermatitis and covid-19. *British journal of dermatology (1951)* 2023;189:486-8.
57 Quan L, Tan J, Hua L, *et al*. Genetic predisposition between coronavirus disease 2019 and rheumatic diseases: a 2-sample mendelian randomization study. *Int. J. Rheum. Dis.* 2023;26:710-7.
58 Sun D, Du Q, Wang R, *et al*. Covid-19 and the risk of neuromyelitis optica spectrum disorder: a mendelian randomization study. *Front. Immunol.* 2023;14:1207514.
59 Sun D, Tu L, Wang X, *et al*. Association between covid-19 and myasthenia gravis (mg): a genetic correlation and mendelian randomization study. *Brain Behav.* 2023;13.
60 Wang S, Wang L, Wang J, *et al*. Causal relationships between susceptibility and severity of covid-19 and neuromyelitis optica spectrum disorder (nmosd) in european population: a bidirectional mendelian randomized study. *Front. Immunol.* 2023;14:1305650.
61 Xu W, Cao Y, Wu L. No causal effects detected in covid-19 and myalgic encephalomyelitis/chronic fatigue syndrome: a two sample mendelian randomization study. *International journal of environmental research and public health* 2023;20:2437.
62 Yang F, Zhang N, Meng R, *et al*. Non-causal association of covid-19 with systemic lupus erythematosus: evidence from a bidirectional mendelian randomization. *J. Infect.* 2023;86:e87-90.
63 Yao M, Huang X, Guo Y, *et al*. Disentangling the common genetic architecture and causality of rheumatoid arthritis and systemic lupus erythematosus with covid-19 outcomes: genome-wide cross trait analysis and bidirectional mendelian randomization study. *J. Med. Virol.* 2023;95.
64 Kong Q, Gao Z, Liu Y, *et al*. Explore genetic susceptibility association between viral infections and guillain-barré syndrome risk using two-sample mendelian randomization. *J. Transl. Med.* 2024;22.

65 Zou Y, Pan M, Zhou T, *et al*. Critical covid-19, victivallaceae abundance, and celiac disease: a mediation mendelian randomization study. *PLoS One* 2024;19:e301998.
66 Gao X, Shen S, Xiang W, *et al*. No causal effect of covid-19 on varicella-zoster infection, herpes zoster progression, and postherpetic neuralgia: a two-sample mendelian randomization study. *Clinical, Cosmetic and Investigational Dermatology* 2024;Volume 17:1423-8.
67 Wang T, Zhang Y, Wu C, *et al*. Exploring the mechanism of comorbidity in patients with t1dm and covid-19: integrating bioinformatics and mendelian randomization methods. *Medicine. (Baltimore).* 2024;103:e40128.
68 Li GH, Tang C, Cheung C. Covid-19 and thyroid function: a bi-directional two-sample mendelian randomization study. *Thyroid.* 2022;32:1037-50.
69 Cao H, Baranova A, Wei X, *et al*. Bidirectional causal associations between type 2 diabetes and covid-19. *J. Med. Virol.* 2023;95.
70 Zhang K, Gao H, Chen M. Genetic susceptibility tocovid -19 may increase the risk of erectile dysfunction: a two-samplemendelian randomization study. *Andrologia* 2022;54.
71 Chang Z, An L, Lei M, *et al*. The genetic associations of covid-19 on genitourinary symptoms. *Front. Immunol*. 2023;14:1216211.
72 Shi H, Zhao H, Zhang W, *et al*. Covid-19 is not a causal risk for miscarriage: evidence from a mendelian randomization study. *J. Assist. Reprod. Genet.* 2023;40:333-41.
73 Si Y, Fei Y, Ma H, *et al*. The causal association between polycystic ovary syndrome and susceptibility and severity of covid-19: a bidirectional mendelian randomization study using genetic data. *Frontiers in endocrinology (Lausanne)* 2023;14:1229900.
74 Lin H, Cao B. Severe covid-19 and chronic kidney disease: bidirectional mendelian randomization study. *Virol. J.* 2024;21:32.
75 Liu Q, Cui Y, Wang X, *et al*. Genetic association between covid-19 and male infertility: a two-sample mendelian randomization analysis. *Journal of men's health (Amsterdam)* 2024;20:62-72.
76 Ma C, Ma L, Wang P. Causal associations between covid-19 and erectile dysfunction: a mendelian randomization study. *J. Int. Med. Res.* 2024;52.
77 Zhang M, Wen T, Wang D. The association between covid-19 and infertility: mendelian randomization analysis. *Medicine. (Baltimore).* 2024;103:e37346.
78 Wu X, Peng H, Xiong S, *et al*. Novel evidence revealed genetic association between covid-19 infection, severity and endometrial cancer. *J. Infect.* 2022;85:e1-3.
79 Dong J, Wang S, Xie H, *et al*. Covid-19 hospitalization increases the risk of developing glioblastoma: a bidirectional mendelian-randomization study. *Front. Oncol*. 2023;13:1185466.
80 Li J, Bai H, Qiao H, *et al*. Causal effects of covid-19 on cancer risk: a mendelian randomization study. *J. Med. Virol*. 2023;95.
81 Song H, Lei N, Zeng L, *et al*. Mendelian randomization analysis identified tumor necrosis factor as being associated with severe covid-19. *Front. Pharmacol.* 2023;14:1171404.
82 Sun Z, Wang S, Sun X, *et al*. Covid-19 has causal effects on cancer risk? Something we might

ignore. *J. Med. Virol.* 2023;95.

83 Wang D, Ma Y, Yan L, *et al*. Exploring the association between covid-19 and male genital cancer risk in european population: evidence from mendelian randomization analysis. *BMC Genomic Data* 2023;24:56.

84 Xu D, Wang X, Zhou D. Exploring the potential association between covid-19 and thyroid cancer: a mendelian randomization study. *ACS Omega* 2023;8:49158-64.

85 Zhao X, Wu X, Xiao J, *et al*. A large-scale genome-wide cross-trait analysis for the effect of covid-19 on female-specific cancers. *iScience* 2023;26:107497.

86 Chen Q, Lu C, Jiang F, *et al*. The association of covid-19 with diffuse large b-cell lymphoma: a mendelian randomization study. *Int. J. Environ. Health Res.* 2024;34:2378-86.

87 Song L, Wu D, Wu J, *et al*. Investigating causal associations between pneumonia and lung cancer using a bidirectional mendelian randomization framework. *BMC Cancer* 2024;24.

88 Wang H, Fang N, Mozumder P, *et al*. Exploring the protective association between covid-19 infection and laryngeal cancer: insights from a mendelian randomization study. *Front. Immunol.* 2024;15.

89 Han B, Sun M, Zhao Y, *et al*. Genetic predisposition to milder forms of covid-19 may provide some resilience to head and neck cancers. *Front. Oncol.* 2024;14.

90 Liu Z, Song L, Chen J, *et al*. Causal associations between chronic hepatitis b and covid-19 in east asian populations. *Virol. J.* 2023;20:109.

91 Lu H, Cao Y, Zhong M. No causal association between covid-19 and sepsis: a bidirectional two-sample mendelian randomization study. *Front. Immunol.* 2023;14:1183489.

92 Song J, Wu Y, Yin X, *et al*. Relationship between periodontitis and covid-19: a bidirectional two-sample mendelian randomization study. *Health Sci. Rep.* 2023;6.

93 Fang Y, Fang D. Mendelian randomization analysis reveals causal relationship between obstetric-related diseases and covid-19. *Virol. J.* 2024;21.

94 Shen Y, Zhang Y, Xu Y, *et al*. Causal associations between severe covid-19 and diseases of seven organs: a proteome-wide mendelian randomization study. *Front. Genet.* 2024;15.

95 Zhang X, Jiang Z, Ma J, *et al*. Leveraging large-scale genetic data to assess the causal impact of covid-19 on multisystemic diseases. *J. Big Data* 2024;11.

96 Ran S, Yao J, Liu B. The association between covid-19 and cognitive performance: a mendelian randomization analysis. *Alzheimers. Dement.* 2023;19:2742-4.

97 Wan Y, Shang J, Graham R, *et al*. Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus. *J. Virol.* 2020;94.

98 Bangalore S, Sharma A, Slotwiner A, *et al*. St-segment elevation in patients with covid-19 - a case series. *N. Engl. J. Med.* 2020;382:2478-80.

99 Nannoni S, de Groot R, Bell S, *et al*. Stroke in covid-19: a systematic review and meta-analysis. *Int. J. Stroke* 2021;16:137-49.

100 Mao L, Jin H, Wang M, *et al*. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, china. *JAMA Neurol.* 2020;77:683.

101 Ellul MA, Benjamin L, Singh B, *et al*. Neurological associations of covid-19. *Lancet Neurol.* 2020;19:767-83.

102 Sun T, Guan J. Novel coronavirus and the central nervous system. *Eur. J. Neurol*. 2020;27:e52.

103 Nannoni S, de Groot R, Bell S, *et al*. Stroke in covid-19: a systematic review and meta-analysis. *Int. J. Stroke* 2021;16:137-49.



Source: Page MJ, et al. BMJ 2021;372:n71. doi: 10.1136/bmj.n71.

This work is licensed under CC BY 4.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/


SS
I²(%)
Forest plots
OR (95% CI)
CNS
NS 14 67.00 1.005(0.995, 1.015)
MS 9 28.60 1.002(0.999, 1.005)
Overall 23 58.60 1.003(0.998, 1.007)
CVS
CSFCs 7 33.90 0.999(0.988, 1.011)
CVD 9 66.70 1.019(1.011, 1.027)
Overall 16 57.70 1.013(1.006, 1.019)
GU
Rs 5 11.40 1.007(0.991, 1.022)
US 3 0.00 0.990(0.969, 1.011)
Overall 8 0.00 1.000(0.993, 1.008)
DS
DS 5 17.10 1.002(0.994, 1.010)
AD
AD 15 23.90 1.006(0.987, 1.025)
Tu
Tu 12 19.20 1.003(0.995, 1.012)
ES
ES 2 61.20 1.011(0.990, 1.032)
IDs
IDs 3 0.00 0.994(0.967, 1.022)
0.9
1.0
1.1
Positive effect (P<0.05)
No significant (P≥0.05)


Forest plots
SS
I²(%)
OR (95% CI)
CNS
CD 3 65.30 0.860(0.774, 0.945)
Epilepsy 32 68.30 1.087(1.053, 1.122)
Optic nerve 5 51.70 1.444(1.080, 1.807)
GAD 6 0.00 1.010(1.006, 1.015)
SCZ 8 37.60 1.048(1.014, 1.081)
CVS
MI 7 9.40 0.978(0.962, 0.993)
Pericarditis 3 0.00 0.900(0.825, 0.975)
Stroke 16 39.20 1.031(1.018, 1.043)
DS
IBS 3 0.00 1.039(1.014, 1.063)
ES
T2DM 7 49.5 1.076(1.022, 1.129)
AD
Celiac disease 3 0.00 1.111(1.011, 1.211)
MG 9 0.00 1.096(1.029, 1.162)
NMOSD 12 0.00 1.292(1.099, 1.484)
RA 4 0.00 0.976(0.954, 0.999)
GU
Urolithiasis 3 0.00 1.293(1.043, 1.543)
SD 3 0.00 1.093(1.026, 1.160)
TD 3 0.00 1.326(1.095, 1.557)
TT 3 0.00 0.772(0.554, 0.990)
Tu
EC 6 0.00 1.083(1.047, 1.120)
GBM 6 0.00 1.085(1.001, 1.170)
LC 6 0.00 0.553(0.368, 0.737)
LOPC 3 0.00 0.740(0.507, 0.973)
SC 6 0.00 1.270(1.129, 1.410)
0.5
1.0
1.5
Negative effect (P<0.05)
Positive effect (P<0.05)